Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095226 Target Snapshot

Integrin alpha-5/beta-1 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
569Compounds
113Assays
0Approved Drugs
790.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Integrin alpha-5/beta-1 shows clinical signal disease relevance led by lung cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05556. Start with lung cancer, then reuse UniProt P05556 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with lung cancer, then reuse UniProt P05556 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
lung cancer

Integrin alpha-5/beta-1 shows clinical signal disease relevance led by lung cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with lung cancer because it currently carries clinical signal support. Linked drugs include VOLOCIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Integrin alpha-5/beta-1 as ChEMBL target CHEMBL2095226, mapped to UniProt P05556. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Integrin alpha-5/beta-1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095226
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P05556
Integrin beta-1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Integrin alpha-5/beta-1 is the right protein anchor across sources, using UniProt P05556 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why lung cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntegrin alpha-5/beta-1
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP05556
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntegrin beta-1
UniProt AccessionP05556
Component TypeProtein
Sequence Length798 aa

Integrin beta-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Integrin alpha-5/beta-1, mapped to UniProt P05556. ChEMBL maps the protein component as Integrin beta-1. Sequence length is 798 aa.

Mapped IDP05556
Review nameIntegrin alpha-5/beta-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Integrin alpha-5/beta-1 shows clinical signal disease relevance led by lung cancer. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVOLOCIXIMAB
Clinical signal Phase II
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVOLOCIXIMAB
Clinical signal Phase II
ovarian cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVOLOCIXIMAB
Clinical signal Phase II
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVOLOCIXIMAB
Clinical signal Phase II
peritoneal neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugVOLOCIXIMAB
Clinical signal Phase II
renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugATN-161
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with lung cancer because it currently carries clinical signal support. Linked drugs include VOLOCIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaselung cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
2
Phase I
Assay Mix

Activity Type Distribution

IC50755.0
KI1.0
EC5030.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL565693 10.0 IC50 0.1 Preclinical
CHEMBL338439 9.74 IC50 0.18 Preclinical
CHEMBL4241824 9.59 Kd 0.257 Preclinical
CHEMBL1077192 9.52 IC50 0.3 Preclinical
CHEMBL5786200 9.52 IC50 0.3 Preclinical
CHEMBL126071 9.41 IC50 0.39 Preclinical
CHEMBL3319235 9.41 IC50 0.39 Preclinical
CHEMBL5790208 9.3 IC50 0.5 Preclinical
CHEMBL5964326 9.3 IC50 0.5 Preclinical
CHEMBL396014 9.27 IC50 0.54 Preclinical
Distribution

pChEMBL Value Distribution

63
5.0
53
5.5
97
6.0
64
6.5
89
7.0
61
7.5
49
8.0
33
8.5
51
9.0
7
9.5
pChEMBL
Assay Landscape

Assay Landscape

113
Total Assays
427
Tested Compounds
2
Assay Types
Binding — 94 assays, 427 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 48 309 7.3
cell-based format 42 78 6.8
assay format 3 33 6.2
tissue-based format 1 7 7.5
Functional — 19 assays, 76 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 17 58 6.4
assay format 2 18 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine